NOVO 02
Has been approved as an adjunct to conventional chemotherapy in Russia.
BUT, is still waiting for FDA approval in the USA
Manufactured by Novelos Therapeutics (NVLT.ob)
Cures 80% more cancer patients than conventional Chemo.
In Russian studies and one US study NOV-002 allowed cancer patients to become 100% tolerant to conventional chemo.
How come NOV-002 is not FDA approved?
Could have saved so many lives!
2007-01-07
07:16:51
·
4 answers
·
asked by
Bixbyte
4
in
Health
➔ Diseases & Conditions
➔ Cancer
Sorry, I forgot to mention that Novelos Therapeutics Adjunct Chemotherapy medication.
NOV 002 Has been granted Fast Track and SPA (special protocol assessment) By the FDA
here is part of the news release:
Novelos Therapeutics Obtains FDA Fast Track Designation for NOV-002 Lung Cancer Treatment
Monday August 7, 8:30 am ET
NEWTON, Mass.--(BUSINESS WIRE)--Aug. 7, 2006--Novelos Therapeutics, Inc. (OTCBB: NVLT - News), a biotechnology company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the Food and Drug Administration (FDA) has granted Fast Track designation to NOV-002 for use in combination with first-line chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). The FDA's Fast Track program is designed to facilitate the development and accelerate the review process for new drugs that have the potential to address a serious and unmet medical need for conditions such as advanced NSCLC.
2007-01-07
08:13:18 ·
update #1